Cargando…
Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study
BACKGROUND: This phase 1b study evaluated the pharmacokinetics, safety, and antiviral effects of the respiratory syncytial virus (RSV)–specific fusion inhibitor JNJ-53718678 (JNJ-8678) in hospitalized RSV-infected patients aged > 1 to ≤24 months. METHODS: Patients categorized by age (cohort 1: ≥6...
Autores principales: | Martinón-Torres, Federico, Rusch, Sarah, Huntjens, Dymphy, Remmerie, Bart, Vingerhoets, Johan, McFadyen, Katie, Ferrero, Fernando, Baraldi, Eugenio, Rojo, Pablo, Epalza, Cristina, Stevens, Marita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744997/ https://www.ncbi.nlm.nih.gov/pubmed/32201897 http://dx.doi.org/10.1093/cid/ciaa283 |
Ejemplares similares
-
1958. Antiviral Effects, Pharmacokinetics (PK), and Safety of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected Infants With Bronchiolitis, in the Phase 1b Study 53718678RSV1005
por: Martinon-Torres, Federico, et al.
Publicado: (2018) -
Respiratory Syncytial Virus (RSV) Neutralizing Antibodies at Birth Predict Protection from RSV Illness in Infants in the First 3 Months of Life
por: Buchwald, Andrea G, et al.
Publicado: (2020) -
Monitoring Severity of Respiratory Syncytial Virus (RSV) in Infants and Young Children Using the Pediatric RSV Electronic Severity and Outcome Rating System (PRESORS): Results of Initial Quantitative Validation
por: de la Loge, Christine, et al.
Publicado: (2021) -
COVID-19 Lesson for Respiratory Syncytial Virus (RSV): Hygiene Works
por: Gastaldi, Andrea, et al.
Publicado: (2021) -
Respiratory Syncytial Virus (RSV)
por: Walsh, Edward E., et al.
Publicado: (2015)